EMERYVILLE, Calif., Feb. 27, 2018 (GLOBE NEWSWIRE) -- Zogenix, Inc. (NASDAQ:ZGNX), a pharmaceutical company developing therapies for the treatment of rare central nervous system (CNS) disorders, today announced that it will report its financial results for the fourth quarter and full-year ended December 31, 2017, after the market close, and will host a corporate update conference call and webcast on Tuesday, March 6, 2018, at 4:30 PM Eastern Time.
| Conference Call Details | |||||||
| Tuesday, March 6th @ 4:30 PM Eastern Time/1:30 PM Pacific Time | |||||||
| Toll Free: | 800-239-9838 | ||||||
| International: | 323-794-2551 | ||||||
| Conference ID: | 5092266 | ||||||
| Webcast: | http://public.viavid.com/index.php?id=128365 | ||||||
| Replays, available through March 20: | |||||||
| Domestic: | 844-512-2921 | ||||||
| International: | 412-317-6671 | ||||||
| Replay PIN: | 5092266 | ||||||
About Zogenix
Zogenix, Inc. (Nasdaq:ZGNX) is a pharmaceutical company committed to developing and commercializing CNS therapies that address specific clinical needs for people living with orphan and other CNS disorders who need innovative treatment alternatives to improve their daily functioning.
For more information, visit www.zogenix.com.
CONTACT:
Investors: Andrew McDonald
Founding Partner, LifeSci Advisors LLC
646-597-6987 | Andrew@lifesciadvisors.com